Clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent brain glioma / 中南大学学报(医学版)
Journal of Central South University(Medical Sciences)
;
(12): 394-397, 2018.
Artigo
em Chinês
| WPRIM
| ID: wpr-693828
ABSTRACT
Objective:
To investigate the clinical efficacy of stereotactic radiation therapy combined with temozolomide on recurrent glioma.Methods:
A total of 36 patients with recurrent glioma were retrospectively analyzed and divided into a control group (n=12),who received stereotactic radiation therapy,and an experimental group (n=24),who received stereotactic radiation therapy plus temozolomide.The clinical efficacy and adverse reactions for the 2 groups were compared.Results:
Total effective rate and local control rate for clinical treatment were 66.67% and 93.94%,respectively.Late adverse reaction was not observed.The effective rate and local control rate in the experimental group were 77.27% and 95.45%,which were slight higher than those in the control group,with no statistical significance (P>0.05).The 0.5-,1-,2-,3-year follow-up total survival rates were 90.91%,63.64%,42.42%,and 15.15%,respectively.The 0.5-,1-,2-,3-year follow-up survival rates in the experimental group were 95.45%,72.72%,54.54% and 22.73%,respectively,while those in the control group were 81.82%,45.45%,18.18%,and 0%,respectively.Survival analysis showed the survival time for the experimental group was significantly longer than that of the control group (30.00 months vs 14.00 months,P=0.010).Conclusion:
Stereotactic radiation therapy combined with temozolomide for recurrent glioma is effective,and it has positive effect on improving the clinical efficacy and survival rate for the patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Central South University(Medical Sciences)
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS